Tiespectus for Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Recruiting
Phase 2
Phase 3
Interventional Study
Macular Degeneration
Age-Related Macular Degeneration
Choroidal Neovascularization
Wet Macular Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 960 (estimated)
- Sponsor
- EyeBiotech Ltd. · Industry
Who this trial is looking for
This trial is looking for people with new cases of neovascular age-related macular degeneration. Participants will receive a trial medication called tiespectus to see if it works as well as standard treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with neovascular age-related macular degeneration within the last 21 days
- I have choroidal neovascularization in at least one eye
You may not be able to join if
- I have uncontrolled blood pressure
- I have had macular laser treatment in the study eye
- I have a history of uveitis in either eye
- I have had cataract surgery or similar eye procedures in the study eye in the last 90 days
- I have uncontrolled glaucoma in the study eye
- I have active retinal disease other than the study condition
- I have previously received anti-VEGF treatment in the study eye
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to tre…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
The main inclusion criteria include but are not limited to the following:
* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal …
Contacts